PT  - JOURNAL ARTICLE
AU  - Culmer, P.
AU  - Birch, W. Davis
AU  - Waters, I.
AU  - Keeling, A.
AU  - Osnes, C.
AU  - Jones, D.
AU  - de Boer, G.
AU  - Hetherington, R.
AU  - Ashton, S.
AU  - Latham, M.
AU  - Beacon, T.
AU  - Royston, T.
AU  - Miller, R.
AU  - Littlejohns, A.
AU  - Parmar, J.
AU  - Lawton, T.
AU  - Murdoch, S.
AU  - Brettle, D.
AU  - Musasizi, R.
AU  - Nampiina, G.
AU  - Namulema, E.
AU  - Kapur, N.
TI  - The LeVe CPAP System for oxygen-efficient CPAP respiratory support: Development and pilot evaluation
AID  - 10.1101/2021.05.24.21256987
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.24.21256987
4099  - http://medrxiv.org/content/early/2021/05/26/2021.05.24.21256987.short
4100  - http://medrxiv.org/content/early/2021/05/26/2021.05.24.21256987.full
AB  - Background The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has placed a significant demand on healthcare providers (HCPs) to provide respiratory support for patients with moderate to severe symptoms. Continuous Positive Airway Pressure (CPAP) non-invasive ventilation can help patients with moderate symptoms to avoid the need for invasive ventilation in intensive care. However, existing CPAP systems can be complex (and thus expensive) or require high levels of oxygen, limiting their use in resource-stretched environments.Technical Development + Testing The LeVe (“Light”) CPAP system was developed using principles of frugal innovation to produce a solution of low complexity and high resource efficiency. The LeVe system exploits the air flow dynamics of electric fan blowers which are inherently suited to delivery of positive pressure at appropriate flow rates for CPAP. Laboratory evaluation demonstrated that performance of the LeVe system was equivalent to other commercially available systems used to deliver CPAP.Pilot Evaluation The LeVe CPAP system was tested to evaluate safety and acceptability in a group of ten healthy volunteers at Mengo Hospital in Kampala, Uganda. The study demonstrated that the system can be used safely without inducing hypoxia or hypercapnia and that its use was well tolerated by users, with no adverse events reported.Conclusions CPAP ventilation systems provide an important treatment option for COVID-19 patients. To deliver this for the high patient numbers associated with the COVID-19 pandemic, healthcare providers require resource efficient solutions. We have shown that this can be achieved through frugal engineering of a CPAP ventilation system, in a system which is safe for use and well tolerated in healthy volunteers. This approach may also benefit other respiratory conditions which often go unaddressed in LMICs for want of context-appropriate technology.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialPACTR202105734146484Funding StatementThis project was supported by funding from the UK Global Challenges Research Fund (GCRF) through the University of Leeds.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mengo Hospital (Kampala, Uganda) IRB and the Uganda National Council for Science and Technology approved this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available by reasonable request from the corresponding authors. https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=15875